Indolent Lymphoma
Commentary
Unleashing Our Immune Response to Quash Cancer
“It’s astounding how devious cancer cells and tumor tissue can be.”
News
FDA approves pirtobrutinib for previously treated CLL/SLL
FDA greenlights pirtobrutinib as third-line treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma in adults.
News
FDA OKs new agent to block chemotherapy-induced neutropenia
Efbemalenograstim has been approved by the FDA to combat infections in adults being treated for nonmyeloid cancers.
Conference Coverage
Ocular MALT lymphoma: Radiation reduces relapse
Mortality rates from early-stage ocular MALT lymphoma are low, with relapse rates lowered by radiation therapy.
From the Journals
ESMO helps hematologists assess new cancer drugs
The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies...
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
CBSM phone app eases anxiety, depression in cancer patients
Few patients with cancer have access to psycho-oncologic support.
Conference Coverage
Huge underuse of germline testing for cancer patients
Information from germline genetic testing could affect a patient’s cancer care.
Conference Coverage
DEI training gives oncology fellows more confidence
Only 2%-3% of practicing oncologists are Black or Hispanic/Latino, says Yale Cancer Center doctor.
Feature
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Feature
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.